logo-loader
viewTissue Regenix Group PLC

Tissue Regenix chief Antony Odell on their 'transformational' Cellright acquisition

Antony Odell, chief executive of Tissue Regenix PLC (LON:TRX) tells Proactive they're spending US$30mln on Texas-based rival, Cellright Technologies, which will catapult them to the front of  the growing US market for regenerative medicine and bone grafts.

Quick facts: Tissue Regenix Group PLC

Price: 1.55 GBX

AIM:TRX
Market: AIM
Market Cap: £18.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

4 weeks, 1 day ago

2 min read